Division of Cancer Prevention: Collaborations with China

Joint Meeting of the National Cancer Advisory Board and the Board of Scientific Advisors

Barry Kramer, MD, MPH, Director, NCI Division of Cancer Prevention

NIH NATIONAL CANCER INSTITUTE

June 24, 2015
Primary Collaborations with China

- Cancer Screening Trial Feasibility Study
- China Early Detection Research Network
- Chinese Translation of the PDQ Database

Primary Collaborators:

- National Institute/Hospital of Chinese Academy of Medical Sciences, National Cancer Center (CICAMS, NCC)
- DCP serving in an advisory capacity, providing consultation and technical support
- NCI Office of Communications and Public Liaison
China Cancer Screening Trial Feasibility Study

- Lung and colorectal cancer screening
- Confirm NLST results in Chinese urban population
- Practicability of population-based screening for colorectal cancer in China
- Feasibility study for a long-term randomized 3-arm screening trial
Feasibility Study Design

- 3 Cities in Urban China (socioeconomic status)
  Hangzhou (high), Changsha (middle), Lanzhou (low)
- 3 Study Arms (2700 participants; 900 in each center)
  1) Helical chest CT exam annually + one-time colonoscopy
  2) Helical chest CT biennially + OC-FIT for colon cancer annually
  3) Septin9 + InSureFIT for colon cancer annually
Study Timeline

- May 2013: Memorandum of Understanding signed
- June 2014: China IRB study approval
- Sep 2014: Began recruitment/enrollment
- Sep 2014 - Mar 2015: $T_0$ Baseline screenings
- Aug - Dec 2015: $T_1$ screenings
- Aug - Dec 2016: $T_2$ screenings
## Center Recruitment by Province *Main City*

<table>
<thead>
<tr>
<th></th>
<th>Gansu</th>
<th>Hunan</th>
<th>Zhejiang</th>
<th>TOTAL</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Lanzhou (lower SES)</td>
<td>Changsha (middle SES)</td>
<td>Hangzhou (higher SES)</td>
<td></td>
</tr>
<tr>
<td>Invited</td>
<td>11,231</td>
<td>8,000</td>
<td>1,500</td>
<td>20,731</td>
</tr>
<tr>
<td>Eligible</td>
<td>4,680</td>
<td>1,500</td>
<td>1,003</td>
<td>7,183</td>
</tr>
<tr>
<td>Randomized</td>
<td>900</td>
<td>904</td>
<td>900</td>
<td>2,704</td>
</tr>
</tbody>
</table>
## LDCT Screening Preliminary Data
(April 15, 2015, by Province, Main City)

<table>
<thead>
<tr>
<th></th>
<th>Gansu Lanzhou</th>
<th>Hunan Changsha</th>
<th>Zhejiang Hangzhou</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong># Screened</strong></td>
<td>543</td>
<td>519</td>
<td>542</td>
</tr>
<tr>
<td><strong>CT Lung Abnormality</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>436 (80.3%)</td>
<td>469 (90.4%)</td>
<td>336 (62.0%)</td>
</tr>
<tr>
<td>No</td>
<td>107 (19.7%)</td>
<td>50 (9.6%)</td>
<td>206 (38.0%)</td>
</tr>
<tr>
<td><strong>Non-calcified Nodule/Mass</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;4mm</td>
<td>0 (0.0%)</td>
<td>87 (18.6%)</td>
<td>53 (15.8%)</td>
</tr>
<tr>
<td>≥4mm</td>
<td>14 (3.2%)</td>
<td>36 (7.7%)</td>
<td>47 (14.0%)</td>
</tr>
</tbody>
</table>
China Early Detection Research Network (China-EDRN)

- China’s leadership interest in establishing an EDRN infrastructure to meet China’s needs
- Joint monthly U.S.-China conference calls
- US-EDRN informatics center (Jet Propulsion Laboratory) assisting in establishing China databases
- Collaborative research opportunities with China-EDRN investigators
- China Visiting Scientist at NCI, Apr-Oct 2015
Chinese Translation of the PDQ Database

- Collaboration with NCI’s Office of Communications and Public Liaison
- Extending the reach of PDQ cancer information to the Chinese-speaking health professionals
- Pilot phase: Health professional summaries and supporting documents for six cancer types of highest public health interest in China
- Translation and review by content experts completed May 2015
- Construction of website underway